These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32601172)

  • 1. Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease.
    Nikolopoulos DS; Kostopoulou M; Pieta A; Flouda S; Chavatza K; Banos A; Boletis J; Katsimbri P; Boumpas DT; Fanouriakis A
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32601172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the 'Attikon' cohort.
    Nikolopoulos D; Kostopoulou M; Pieta A; Karageorgas T; Tseronis D; Chavatza K; Flouda S; Rapsomaniki P; Banos A; Kremasmenou E; Tzavara V; Katsimbri P; Fanouriakis A; Boumpas DT
    Lupus; 2020 Apr; 29(5):514-522. PubMed ID: 32106788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years.
    Taraborelli M; Cavazzana I; Martinazzi N; Lazzaroni MG; Fredi M; Andreoli L; Franceschini F; Tincani A
    Lupus; 2017 Oct; 26(11):1197-1204. PubMed ID: 28420047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
    Mikdashi J; Handwerger B
    Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials.
    Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
    Rheumatol Int; 2024 Sep; 44(9):1679-1689. PubMed ID: 39115551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus.
    Ruiz-Irastorza G; Egurbide MV; Martinez-Berriotxoa A; Ugalde J; Aguirre C
    Lupus; 2004; 13(12):900-5. PubMed ID: 15645743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus.
    Mikdashi J; Krumholz A; Handwerger B
    Neurology; 2005 Jun; 64(12):2102-7. PubMed ID: 15985581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
    Wang M; Gladman DD; Ibañez D; Urowitz MB
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):833-7. PubMed ID: 22290935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?
    Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA;
    Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus.
    Ramirez GA; Canti V; Del Rosso S; Erra R; Moiola L; Magnoni M; Bozzolo EP; Manfredi AA; Rovere-Querini P
    Autoimmunity; 2020 Feb; 53(1):21-27. PubMed ID: 31782311
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuropsychiatric manifestations in a consecutive cohort of systemic lupus erythematosus; a single center study.
    Abdul-Sattar AB; Goda T; Negm MG
    Int J Rheum Dis; 2013 Dec; 16(6):715-23. PubMed ID: 24382281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
    Hawro T; Bogucki A; Krupińska-Kun M; Maurer M; Woźniacka A
    PLoS One; 2015; 10(3):e0119911. PubMed ID: 25781014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus.
    Fragoso-Loyo HE; Sánchez-Guerrero J
    J Rheumatol; 2007 Jan; 34(1):76-80. PubMed ID: 17143970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus.
    Aso K; Kono M; Kono M; Watanabe T; Shimizu Y; Ogata Y; Fujieda Y; Kato M; Oku K; Amengual O; Yasuda S; Atsumi T
    Lupus; 2020 Sep; 29(10):1238-1247. PubMed ID: 32635880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival.
    Artım-Esen B; Çene E; Şahinkaya Y; Erdugan M; Oğuz E; Gül A; Öcal L; İnanç M
    Lupus; 2019 Oct; 28(12):1480-1487. PubMed ID: 31558101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard.
    Fanouriakis A; Pamfil C; Rednic S; Sidiropoulos P; Bertsias G; Boumpas DT
    Clin Exp Rheumatol; 2016; 34(5):910-917. PubMed ID: 27463840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus.
    Tomietto P; Annese V; D'agostini S; Venturini P; La Torre G; De Vita S; Ferraccioli GF
    Arthritis Rheum; 2007 Dec; 57(8):1461-72. PubMed ID: 18050188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement.
    Nieves-Plaza M; Ortiz AP; Colón M; Molina MJ; Castro-Santana LE; Rodríguez VE; Mayor AM; Vilá LM
    J Clin Rheumatol; 2011 Jun; 17(4):179-84. PubMed ID: 21617555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.